Yüklüyor......
Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
Nintedanib is a tyrosine kinase inhibitor used to treat idiopathic pulmonary fibrosis (IPF). We investigated the cardiovascular safety of nintedanib using pooled data from the TOMORROW and INPULSIS trials. Cardiovascular events were assessed post hoc in patients with a history of atherosclerotic car...
Kaydedildi:
| Yayımlandı: | Eur Respir J |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
European Respiratory Society
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6766682/ https://ncbi.nlm.nih.gov/pubmed/31285303 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.01797-2018 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|